A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Ramucirumab (Primary) ; Gimeracil/oteracil/tegafur; Oxaliplatin; Paclitaxel
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Aug 2017 Planned End Date changed from 1 Oct 2018 to 1 Nov 2018.
    • 18 May 2017 Planned End Date changed from 1 Nov 2018 to 1 Oct 2018.
    • 18 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top